Raasveld, Floris V.
Caragher, Seamus P.
Kumar, Nicolas
Lehle, Carla H.
Chitneni, Ahish
Valerio, Ian L.
Eberlin, Kyle R.
Hao, David
Article History
Accepted: 5 March 2025
First Online: 17 March 2025
Declarations
:
: This work was in part supported by the Jesse B. Jupiter / Wyss Medical Foundation Endowment. IV is a consultant for AxoGen Inc, Checkpoint Surgical Inc, and Integra Lifesciences Inc. KE is a consultant for AxoGen Inc, Checkpoint Surgical Inc, Integra Lifesciences Inc, Tissium, Tulavi Therapeutics Inc, and Biocircuit. FR, SC, NK, CL, AC, and DH have nothing to disclose.
: The authors declare no competing interests.